ID

34479

Descripción

Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01784757

Link

https://clinicaltrials.gov/show/NCT01784757

Palabras clave

  1. 17/1/19 17/1/19 -
  2. 22/5/19 22/5/19 -
Titular de derechos de autor

GSK group of companies

Subido en

17 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostate Cancer NCT01784757

Eligibility Prostate Cancer NCT01784757

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
written informed consent (ic) obtained.
Descripción

ID.1

Tipo de datos

boolean

histologically confirmed adenocarcinoma of prostate
Descripción

ID.2

Tipo de datos

boolean

progressive metastatic disease
Descripción

ID.3

Tipo de datos

boolean

ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (lhrh) analogue or antagonist or bilateral orchiectomy
Descripción

ID.4

Tipo de datos

boolean

adequate bone marrow, hepatic and renal function
Descripción

ID.5

Tipo de datos

boolean

able to swallow the odm-201 whole as a capsule or tablet.
Descripción

ID.6

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous chemotherapy for prostate cancer.
Descripción

ID.7

Tipo de datos

boolean

known metastases in the brain.
Descripción

ID.8

Tipo de datos

boolean

history of other malignancy within the previous 5 years, except a basal cell carcinoma of skin.
Descripción

ID.9

Tipo de datos

boolean

known gastrointestinal condition that can significantly affect the absorption of the study treatment.
Descripción

ID.10

Tipo de datos

boolean

Similar models

Eligibility Prostate Cancer NCT01784757

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
written informed consent (ic) obtained.
boolean
ID.2
Item
histologically confirmed adenocarcinoma of prostate
boolean
ID.3
Item
progressive metastatic disease
boolean
ID.4
Item
ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (lhrh) analogue or antagonist or bilateral orchiectomy
boolean
ID.5
Item
adequate bone marrow, hepatic and renal function
boolean
ID.6
Item
able to swallow the odm-201 whole as a capsule or tablet.
boolean
Item Group
C0680251 (UMLS CUI)
ID.7
Item
previous chemotherapy for prostate cancer.
boolean
ID.8
Item
known metastases in the brain.
boolean
ID.9
Item
history of other malignancy within the previous 5 years, except a basal cell carcinoma of skin.
boolean
ID.10
Item
known gastrointestinal condition that can significantly affect the absorption of the study treatment.
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial